EGFR and neoplasm: While acquired resistance limits the clinical benefit of cetuximab currently, an improved understanding of the impact of cetuximab on immune recognition of EGFR-expressing tumor cells may lead to development of novel therapeutic combinations for treating HNSCC patients.